Odyssey Therapeutics, Inc. (ODTX) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Odyssey Therapeutics, Inc. (ODTX) closed at USD 16.60 on 2026-10-14, a change of +1.1 % over the past year, with a market capitalization of USD 844.39M.

Odyssey Therapeutics, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Odyssey Therapeutics, Inc. key figures

Previous close

USD 16.60 (2026-10-14)

1-year change

+1.1 %

Market cap

USD 844.39M

Enterprise value

USD 556.18M

P/E ratio (trailing)

-2.29

P/E ratio (forward)

-4.23

EPS (trailing)

-7.69

EPS (forward)

-4.15

PEG ratio

n/a

Price to book

2.00

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

8.12

Employees

100

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Odyssey Therapeutics, Inc.

Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company pipeline includes OD-001, an oral small molecule inhibitor of receptor-interacting protein kinase 2, which is in phase 2a trial for the treatment of ulcerative colitis; OD-002, an oral small molecule SLC15A4 inhibitor designed to block TLR7/8/9-mediated pathogenic inflammatory responses activation of interferon regulatory factor 5 (IRF5); OD-003, a protein therapeutic designed to agonize tumor necrosis factor receptor 2 selectively on Treg; a TSLP/IL-33 bispecific antagonist; an oral small molecule interleukin-1 receptor–associated kinase 4 scaffolding inhibitor; and a small molecule inhibitor of IRF5. The company was incorporated in 2021 and is headquartered in Boston, Massachusetts.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Odyssey Therapeutics, Inc. and compare it with other stocks.